July 1, 2024Journal of Advanced ResearchOpen Access

Ginsenoside Rh4 inhibits colorectal cancer via the modulation of gut microbiota-mediated bile acid metabolism

View Full Paper

Ask AI

Bookmark

Authors

XBXue BaiShanxi University ZDZhiguang DuanShanxi Medical University JDJianjun DengMinistry of Education of the People's Republic of China

Discussion

Member takes

Implication

Preclinical study demonstrates ginsenoside Rh4 suppresses colorectal cancer in mice, highlighting therapeutic potential for gut microbiota modulation.

Key Points

Colorectal cancer progression is inhibited by ginsenoside Rh4 through the restoration of intestinal barrier integrity and reduction of intestinal inflammation.
Experiments involving fecal microbiota transplantation in an AOM/DSS model reveal enriched Akkermansia muciniphila and enhanced bile acid metabolism.
Highlights therapeutic potential for gut microbiota modulation via ursodeoxycholic acid production; murine model, further preclinical validation needed.

Cite This Study

Bai et al. (2024) studied this question.

synapsesocial.com/papers/68e61ca0b6db6435875aec7c https://doi.org/10.1016/j.jare.2024.06.028

View Full Paper

Ask AI

Bookmark

Implication

Preclinical study demonstrates ginsenoside Rh4 suppresses colorectal cancer in mice, highlighting therapeutic potential for gut microbiota modulation.

Ginsenoside Rh4 inhibits colorectal cancer via the modulation of gut microbiota-mediated bile acid metabolism

Discussion

Member takes

Implication

Key Points

Cite This Study

Ginsenoside Rh4 inhibits colorectal cancer via the modulation of gut microbiota-mediated bile acid metabolism

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider